BioCentury
ARTICLE | Company News

Halozyme gains on CHMP nod for HyQvia

March 23, 2013 12:20 AM UTC

Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.63 (31%) to $6.90 on Friday after EMA's CHMP recommended approval of an MAA for HyQvia from partner Baxter International Inc. (NYSE:BAX) as a replacement therapy for primary immunodeficiency disorders. HyQvia is also recommended as replacement therapy in adults with myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections. The product is a subcutaneous formulation of IV Gammagard, an IgG antibodies plasma-based therapy, and Halozyme's recombinant human PH20 hyaluronidase ( rHuPH20). On a conference call in January to discuss its 4Q12 earnings, Baxter said it expects a decision from the European Commission this half. ...